Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi Aventis intends to acquire branded generics and over-the-counter (OTC) consumer healthcare brands in India, as part of its strategy to offset patent cliff of its bestselling drug Plavix in 2013 and scale up sales from new avenues.
Subscribe to our email newsletter
Apart from eyeing OTC brands across vitamins, mineral supplements, orthopaedic, gynaecology and nutraceutical brands, Sanofi Aventis is also looking for brands in anti-infective, antibiotics, respiratory tract infection and gynaecology products in the branded generics segment, reported The Economic Times.
Even though the Paris-based drug maker has adopted acquisitions route to build generic and consumer healthcare business across Europe, US and Latin America, however, in India its strategy is to fill gaps in product portfolio, reported the newspaper.
Sanofi Aventis, which has forayed into branded generics market specially to tap the rural Indian market in 2009, recently introduced painkiller Combiflam ointment in India as its first consumer healthcare product.
The Economic Times quoted Aventis Pharma MD and Sanofi-Aventis Group (South Aisa) VP Shailesh Ayyangar as saying that the company is going to new territories in India, in order to expand its earlier focus of selling only innovator drugs.
Reportedly, Sanofi was in the race to buy Actis’ 63% stake in Paras Pharmaceuticals, which was eventually acquired by Reckitt Benckiser Group.